Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:08 2024-05-17 EDT			5-day change	1st Jan Change
6.765 ^USD	-4.31%		-1.67%	-15.65%

05-17	Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	CI
05-15	RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	MT

Bausch Health Companies Inc. Reiterates Guidance for the Full Year of 2021

November 02, 2021 at 06:59 am

Bausch Health Companies Inc. reiterated guidance for the full year of 2021. For the full-year revenue range of $8.40 ? $8.60 billion.

Latest news about Bausch Health Companies Inc.

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	05-17	CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	05-15	MT
Bausch Health Companies Inc. Approves Directorate Appointments	05-15	CI
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters	05-14	MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters	05-14	MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court	05-13	MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	05-03	MT
Bausch Health Shares Fall Following Q1 Results	05-02	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	05-02	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	05-02	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	05-02	MT
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
North American Morning Briefing : Stock Futures -2-	05-02	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	05-01	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	05-01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	05-01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	05-01	MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	04-25	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	04-25	MT
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says	04-23	MT
RBC Previews Bausch Health's Q1, Trims Target to US$11	04-23	MT
RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating	04-23	MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	04-22	MT
Bausch Health's Issuer Credit Rating Upgraded by S&P	04-19	MT

Chart Bausch Health Companies Inc.

Duration

Period

More charts

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

6.77 USD

Average target price

9.786 USD

Spread / Average Target

+44.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAUSCH HEALTH COMPANIES INC.	-15.65%	2.48B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals